Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Arcus Biosciences by Year
Arcus Biosciences — Marketable securities, current ($M) ($M)
Gilead Sciences Arcus Biosciences: $759M in FY2025, down 8.3% from a year earlier.
Latest, FY2025
759
Period ended Dec 31, 2025
Change on a year earlier
-8.3%
828 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗
Reported in Arcus Biosciences (RCUS) Form 10-Q / 10-K.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Arcus Biosciences — Marketable securities, current ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 759 | -8.3% | Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗ |
| FY2024 | Dec 31, 2024 | 828 | +31.0% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| FY2023 | Dec 31, 2023 | 632 | -21.3% | Arcus Biosciences (RCUS) Form 10-K (filed 2025-02-25) ↗ |
| FY2022 | Dec 31, 2022 | 803 | +128.8% | Arcus Biosciences (RCUS) Form 10-K (filed 2024-02-21) ↗ |
| FY2021 | Dec 31, 2021 | 351 | -36.8% | SEC Filing ↗ |
| FY2020 | Dec 31, 2020 | 555 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Gilead Sciences Arcus Biosciences ($M), annual FY2020–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus-mkt-sec-cur
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.